Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
436 stopped studies mapped to Squamous Cell Carcinoma and descendants · 91% state a reason
Over the 436 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04034225 | Addition of SNS-301 to Checkpoint Inhibitor Treatment in Metastatic/Recurrent SCCHN | Phase 1 / Phase 2 | terminated | Jul 26, 2019 | Sensei Biotherapeutics, Inc. | Terminated by the sponsor | Other (stated, no rule matched) |
| NCT02582008 | Bupropion Hydrochloride or Patient's Choice for Smoking Cessation in Patients With… | Early Phase 1 | terminated | Oct 21, 2015 | Wake Forest University Health Sciences | Slow accrual | Enrollment / accrual |
| NCT02917629 | ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer… | Phase 2 | terminated | Sep 28, 2016 | National Cancer Institute (NCI) | Low accrual combined with expiration of study drug | Enrollment / accrual |
| NCT03435640 | REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With…(REVEAL) | Phase 1 / Phase 2 | terminated | Feb 19, 2018 | Nektar Therapeutics | Based on the overall results from the Phase 1 part of the study the sponsor decided to end the… | Safety / toxicity |
| NCT03906526 | A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination… | Phase 1 | terminated | Apr 8, 2019 | Celgene | Business objectives have changed | Sponsor / business decision |
| NCT03251417 | Apatinib and Irinotecan Combination Treatment in Unresectable or Metastatic Esophageal… | Phase 2 | terminated | Aug 16, 2017 | Peking University | Because PD-1 antibodies had been proved to be a standard second-line treatment in esophageal… | Other (stated, no rule matched) |
| NCT02213133 | Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas(STARRS) | Phase 2 | terminated | Aug 11, 2014 | Karyopharm Therapeutics Inc | Due to enrollment challenges and availability of other options for lung cancer patients. The… | Safety / toxicity |
| NCT02449681 | Study for Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of… | Phase 2 | terminated | May 20, 2015 | Rain Oncology Inc | Lack of efficacy | Efficacy / futility |
| NCT05472220 | Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive… | Phase 1 | withdrawn | Jul 25, 2022 | Pamela Munster | Sponsor funding | Funding |
| NCT04941365 | Quantifying Systemic Immunosuppression to Personalize Cancer Therapy(SERPENTINE) | N/A | withdrawn | Jun 28, 2021 | Institut du Cancer de Montpellier - Val d'Aurelle | please refer to NCT05621837 | Other (stated, no rule matched) |
| NCT04453046 | Hemopurifier Plus Pembrolizumab in Head and Neck Cancer | N/A | terminated | Jul 1, 2020 | Aethlon Medical Inc. | Lack of Eligible subjects at study site | Other (stated, no rule matched) |
| NCT05393635 | ITIL-168 in Advanced Solid Tumors(DELTA-2) | Phase 1 | withdrawn | May 26, 2022 | Instil Bio | business decision | Sponsor / business decision |
| NCT05219578 | RTX-224 Monotherapy in Patients With Solid Tumors | Phase 1 / Phase 2 | terminated | Feb 2, 2022 | Rubius Therapeutics | The Sponsor terminated study after dosing 2 dose groups (7 pts) and closed trial on 11/30/22.… | Other (stated, no rule matched) |
| NCT03513042 | Early Response Evaluation of Proton Therapy by PET-imaging in Squamous Cell Carcinoma…(ERM-PT-HNSCC) | — | terminated | May 1, 2018 | Leiden University Medical Center | Inclusionrate dropped due to changes in clinical process | Other (stated, no rule matched) |
| NCT04762225 | RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors… | Phase 1 | terminated | Feb 21, 2021 | Repertoire Immune Medicines | Development program terminated | Other (stated, no rule matched) |
| NCT05061940 | This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status… | — | terminated | Sep 30, 2021 | Repertoire Immune Medicines | Development program terminated | Other (stated, no rule matched) |
| NCT02437916 | Safety Study of AMG 228 to Treat Solid Tumors | Phase 1 | terminated | May 8, 2015 | Amgen | not stated | Not stated |
| NCT04242173 | Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC | Phase 2 | terminated | Jan 27, 2020 | H. Lee Moffitt Cancer Center and Research Institute | Lack of Interest | Other (stated, no rule matched) |
| NCT01891695 | OPSCC N0 Nodal Control With Reduced IMRT | N/A | terminated | Jul 3, 2013 | Paul W. Read, MD | Study had very specific inclusion/exclusion criteria and difficult to recruit | Enrollment / accrual |
| NCT02295540 | Hypofractionated Radiation Therapy Followed by Surgery in Treating Patients With Advanced… | N/A | withdrawn | Nov 20, 2014 | Rutgers, The State University of New Jersey | slow accrual | Enrollment / accrual |
| NCT04985825 | Imgatuzumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma(I-PACE) | Phase 2 | withdrawn | Aug 2, 2021 | Pega-One S.A.S. | Business decision | Sponsor / business decision |
| NCT04060342 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With… | Phase 1 | terminated | Aug 19, 2019 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | No clear benefit of GB1275 was observed either as monotherapy or in combination with pembrolizumab. | Other (stated, no rule matched) |
| NCT03862066 | Memory Phenotype and PD-1 Inhibition Response in Oral Cancer | — | terminated | Mar 5, 2019 | Medical University of South Carolina | Low accrual progress per internal scientific review committee | Enrollment / accrual |
| NCT04831450 | Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC) | Phase 2 | withdrawn | Apr 5, 2021 | University of Miami | Investigator Decision | Investigator |
| NCT04001413 | Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients | Phase 2 | withdrawn | Jun 28, 2019 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Sponsor withdrew funding | Funding |
| NCT03720158 | Enteral Omega 3 During Radiotherapy to Improve the Quality of Life and Functionality of… | N/A | terminated | Oct 25, 2018 | Coordinación de Investigación en Salud, Mexico | The activities in the study hospital were seriously impacted by the medical care of COVID patients,… | COVID-19 / pandemic |
| NCT04596033 | TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy | Phase 1 | terminated | Oct 22, 2020 | Genocea Biosciences, Inc. | Business reasons | Sponsor / business decision |
| NCT03041181 | Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or… | Phase 2 | terminated | Feb 2, 2017 | Nasser Hanna, M.D. | Funder decision - lack of accrual | Enrollment / accrual |
| NCT04849377 | RBD-HPV: Risk-Based De-Intensification for HPV+ HNSCC | Phase 2 | withdrawn | Apr 19, 2021 | Icahn School of Medicine at Mount Sinai | lack of eligible participants due to change in study criterias | Other (stated, no rule matched) |
| NCT00573131 | Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in… | Phase 2 | terminated | Dec 13, 2007 | Boston Scientific Corporation | OncoGel did not show any impact on overall tumor response | Other (stated, no rule matched) |
| NCT02837042 | Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma | Phase 2 | terminated | Jul 19, 2016 | University of Alabama at Birmingham | Poor accrual | Enrollment / accrual |
| NCT03834571 | Testing the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and… | Phase 2 | withdrawn | Feb 8, 2019 | AIDS Malignancy Consortium | Not approved by CTEP | Other (stated, no rule matched) |
| NCT03090412 | Photodynamic Therapy With HPPH Compared to Standard of Care Surgery in Treating Patients… | Phase 2 | terminated | Mar 24, 2017 | Roswell Park Cancer Institute | low accrual | Enrollment / accrual |
| NCT04625543 | Neoadjuvant Immunotherapy to ESCC | Phase 2 | withdrawn | Nov 12, 2020 | Qilu Hospital of Shandong University | insufficient money | Other (stated, no rule matched) |
| NCT04003025 | Body Composition and Prognosis in Head and Neck Squamous Cell Carcinoma (HNSCC)(HNCAX01) | — | withdrawn | Jul 1, 2019 | Instituto do Cancer do Estado de São Paulo | The proposed analysis was not feasible. | Other (stated, no rule matched) |
| NCT04272333 | Intratumoral Microdosing of Motolimod in HNSCC | Early Phase 1 | terminated | Feb 17, 2020 | Presage Biosciences | Partner Termination | Other (stated, no rule matched) |
| NCT05234606 | A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1… | Phase 1 / Phase 2 | withdrawn | Feb 10, 2022 | Silverback Therapeutics | Sponsor decision based on strategic re-alignment | Sponsor / business decision |
| NCT04428047 | Evaluation of Bintrafusp Alfa in Operable and Untreated Head and Neck Squamous Cell…(ICING) | Phase 2 | terminated | Jun 11, 2020 | UNICANCER | Sponsor decision following information on cases of hyperprogression and early toxicities with… | Safety / toxicity |
| NCT04266470 | Monitoring Blood Flow and Metabolic Activity in Malignant Tissue of Head and Neck Region | N/A | withdrawn | Feb 12, 2020 | Wake Forest University Health Sciences | Study is no longer feasible at our site. | Other (stated, no rule matched) |
| NCT03278626 | Immune Checkpoint Therapy With Nivolumab Esophageal Squamous Cell Carcinoma | Phase 1 / Phase 2 | terminated | Sep 11, 2017 | NYU Langone Health | The study was stopped earlier than anticipated due to slow accrual | Enrollment / accrual |
| NCT03592407 | Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III… | Phase 2 | withdrawn | Jul 19, 2018 | City of Hope Medical Center | Safety concerns | Safety / toxicity |
| NCT01954173 | Adjuvant Radiation for High Risk Bladder Cancer | N/A | terminated | Oct 1, 2013 | Emory University | Slow accrual | Enrollment / accrual |
| NCT02628535 | Safety Study of MGD009 in B7-H3-expressing Tumors | Phase 1 | terminated | Dec 11, 2015 | MacroGenics | Business decision (not for safety reasons) | Safety / toxicity |
| NCT04129320 | Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck | Phase 2 / Phase 3 | withdrawn | Oct 16, 2019 | MacroGenics | Change in study design | Other (stated, no rule matched) |
| NCT05099952 | Sleep and Circadian Rhythm Study in Head and Neck Cancer Patients | N/A | withdrawn | Oct 29, 2021 | Roswell Park Cancer Institute | PI left institute-no accruals | Investigator |
| NCT02901483 | A Study of PEP503 With Radiotherapy in Combination With Concurrent Chemotherapy for… | Phase 1 / Phase 2 | terminated | Sep 15, 2016 | PharmaEngine | bussiness reason | Other (stated, no rule matched) |
| NCT04499352 | A Study to Test BI 754091 Alone or in Combination With BI 836880 in People Who Have… | Phase 2 | withdrawn | Aug 5, 2020 | Boehringer Ingelheim | Not due to safety reasons (sponsor decision). | Safety / toxicity |
| NCT02438995 | Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation… | Phase 1 | terminated | May 8, 2015 | Northwell Health | Low enrollment | Enrollment / accrual |
| NCT04052204 | Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced… | Phase 1 / Phase 2 | terminated | Aug 9, 2019 | Pfizer | Study prematurely terminated as the experimental treatments evaluated in study B9991040 may not… | Other (stated, no rule matched) |
| NCT02952586 | Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC… | Phase 3 | terminated | Nov 2, 2016 | Pfizer | The trial prematurely terminated as recommended by the E-DMC because the boundary for futility has… | Efficacy / futility |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Mar 24, 2023source: clinicaltrials